Hereditary antithrombin deficiency and rEVO Biologics’ ATryn to appear on January 28th TV segment on Lifetime morning show, The Balancing Act™

FRAMINGHAM, Mass.--(BUSINESS WIRE)--rEVO Biologics announced today that hereditary antithrombin (AT) deficiency, and the use of the company’s lead product ATryn antithrombin (Recombinant), will be the focus of a TV segment on Behind the Mystery: Rare and Genetic Diseases, the ground breaking series on The Balancing Act™, America’s premier morning show that airs weekday mornings on Lifetime Television.

The segment will air on Lifetime at 7:00 am (ET/PT) on January 28th, 2013. Along with raising awareness about hereditary AT deficiency, the segment discusses the need for pregnant women to seek simple blood tests to diagnose this genetic disorder. See a preview of the segment at: http://www.thebalancingact.com/video/?v=WXQR2RL6Q04412]

Dr. Michael Paidas, professor at Yale School of Medicine, and co-director of the Yale Women and Children’s Center for Blood Disorders, will appear on the Behind the Mystery segment to provide important information about hereditary AT deficiency diagnosis and treatment.

About The Balancing Act™ on Lifetime Television
The Balancing Act™, America’s premier morning show airs weekday mornings on Lifetime Television at 7:00 am (ET/PT). These days the modern woman is trying to balance it all and the mission at The Balancing Act™ is to bring solutions to them to help them balance life, career, family and most importantly themselves. The Balancing Act™ is a Branded Entertainment show that entertains, educates, and engages the viewer. Behind the Mystery: Rare and Genetic Diseases made its debut on The Balancing Act™ on November 19, 2012. This series is dedicated to educating the public about rare and genetic diseases and treatments, and provides support through collaborations in education with pharmaceutical companies, foundations, and patient advocacy groups.

About rEVO Biologics
rEVO Biologics is a rare disease company focused on developing and delivering first and next-generation therapeutics that are more cost effective to produce than traditional recombinant therapies. Through its proprietary rPRO Technology platform -- a scalable, transgenic, and cost-effective method of protein production-- rEVO Biologics is bringing safe and reliable therapeutic proteins to address critical medical needs. The company’s lead product, ATryn® Antithrombin (Recombinant), is the first and only plasma-free antithrombin concentrate. ATryn received FDA approval in 2009. The company has a number of products in its pipeline and in clinical trials in the areas of hematology, oncology, genetic disorders and autoimmune disease, and is actively seeking additional indications for its lead product.